Pharmascience International Market Entry in Mexico!

Pharmascience International division has successfully entered in the Mexico market with the launch of Deferasirox Oral Disintegrated Tablet, equivalent to the brand Exjade by Novartis.

“This is an important milestone for Pharmascience as we continue to execute our market expansion in key strategic markets,” says Jacquelin Gagnon Vice-President & General Manager International & US Pharmascience

Pharmascience International has developed and adapted a successful agile business model that responds and evolves with the Mexico Healthcare requirements, delivering a clear value offering for patients.

This is a great team success delivering an important strategic achievement that will enable future expansion within the Mexico market.



Founded in 1983, Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada with over 1,500 employees, and an international presence spanning 50 countries. Pharmascience’s global presence and agile business development model provide patients and healthcare communities around the world with the same quality medicines as are dispensed in Canada. Its R&D team has the extensive expertise necessary for the development of complex injectable and solid oral generic drugs.

Pharmascience has been distributing high-quality, FDA certified generic products in the US since 2017 from our Candiac site. Since its inception in 1983, Pharmascience has invested over $500M in research and development and ranks amongst the top generic manufacturers in Canada, offering over 300 product families in more than 20 dosage forms.  In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.

Published in

Product Launches